• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    $MDRX
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Technology
    Get the next $CMBM alert in real time by email

    Appoints Jonathan Sacks and Bruce Felt to the Board

    Lou Silverman to Succeed Greg Garrison as Chairman

    Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Governance Committee.

    Mr. Sacks is a Partner at Stonehill Capital Management LLC ("Stonehill"), where he has been for over 20 years, and brings deep financial expertise and strategic insight to the Board. At Stonehill he has led and managed debt and equity investments across many industries including healthcare and software. While at Stonehill, Mr. Sacks has had extensive experience investing in companies undergoing complex transitions such as accounting challenges, delistings, and capital structure changes. Stonehill, through funds it manages on behalf of institutional investors and others, is Veradigm's largest shareholder.

    Mr. Felt has served as Chief Financial Officer (CFO) at several public companies in the technology space, including most recently at Domo (NASDAQ:DOMO), a cloud software company that specializes in business intelligence tools and data visualization. During his nearly nine-year tenure as CFO, Mr. Felt oversaw the scaling of Domo's enterprise cloud business and helped take the company public in 2018. Prior to Domo, he served as CFO at SAP SuccessFactors (NASDAQ:SFSF) and FullTime Software (NASDAQ:FTSW), overseeing the sales of both companies. He currently serves on the board of directors of Cambium Networks (NASDAQ:CMBM), including as Audit Committee Chair. Mr. Felt also previously served as lead independent director and Audit Committee Chair at Evolent Health (NYSE:EVH).

    "Veradigm remains focused on strong governance and strategic oversight as we continue to drive innovation and seek to maximize value for our stockholders," said Mr. Garrison. "On behalf of the entire Board, I am pleased to welcome Jonathan and Bruce, who bring deep leadership, financial stewardship, and technology experience to the Board. Additionally, we are confident that with Bruce's extensive financial and accounting background, he is highly qualified to serve as Audit Committee Chair."

    Mr. Garrison continued "I am very pleased that Lou Silverman has agreed to assume the role of Chairman upon my departure. With Lou's 30 years of leadership experience in health information technology and technology-enabled healthcare services, the Board is confident in his ability to lead the Board as it oversees Veradigm's next phase."

    "It will be an honor to serve as Veradigm's Chairman of the Board as the Company navigates this important time," said Mr. Silverman. "I want to thank Greg for his leadership and vision, and I look forward to working closely with the rest of the Board as we focus on our priorities: remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing our growth strategy, and relisting our common stock."

    The appointments of Messrs. Felt and Sacks to the Board satisfy Veradigm's obligations under the February 2025 Cooperation Agreement with Kent Lake PR LLC.

    About Veradigm®

    Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

    © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250318997143/en/

    Investors:

    Jenny Gelinas

    312-506-1237

    [email protected]

    Media:

    Amanda Cohen

    412-919-2417

    [email protected]

    Get the next $CMBM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMBM
    $DOMO
    $EVH
    $MDRX

    CompanyDatePrice TargetRatingAnalyst
    Evolent Health Inc
    $EVH
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Domo Inc.
    $DOMO
    2/13/2026$3.50Mkt Outperform → Mkt Underperform
    Citizens
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Equal-Weight → Overweight
    Stephens
    Evolent Health Inc
    $EVH
    11/13/2025$7.00Outperform
    BMO Capital Markets
    Domo Inc.
    $DOMO
    8/26/2025$21.00Hold → Buy
    TD Cowen
    Domo Inc.
    $DOMO
    7/18/2025$19.00Overweight
    Stephens
    Domo Inc.
    $DOMO
    3/7/2025$9.00 → $8.00Neutral
    DA Davidson
    Domo Inc.
    $DOMO
    2/11/2025$11.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Domo Announces Fourth Quarter and Fiscal 2026 Financial Results

    Domo, Inc. (NASDAQ:DOMO) today announced results for its fiscal fourth quarter and year ended January 31, 2026. Fiscal Fourth Quarter Results Total revenue was $79.6 million, an increase of 1% year over year Subscription revenue was $73.4 million, an increase of 2% year over year Billings were $111.2 million, an increase of 8% year over year Subscription Remaining Performance Obligations (RPO) was $437.9 million as of January 31, 2026, an increase of 8% year over year Current subscription RPO was $227.0 million as of January 31, 2026, an increase of 1% year over year GAAP operating margin was negative 13%, an improvement of 2 percentage points year over year Non-GAAP

    3/10/26 4:05:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Domo Announces Timing of its Fourth Quarter and Full-Year Fiscal 2026 Earnings Conference Call

    Domo (NASDAQ:DOMO) today announced that results for its fourth quarter and full-year fiscal 2026 (ended January 31, 2026) will be released on Tuesday, March 10, 2026, after market close. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live dial-in is available at (877) 484-6065 or (201) 689-8846. A live webcast of the event will also be available on the Domo Investor Relations website at www.domo.com/IR. A replay will be available at (877) 660-6853 or (201) 612-7415 with access ID# 13758775 following the completion of the conference call until 11:59 p.m. (ET) on April 10, 2026. About Domo Do

    2/27/26 9:00:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Evolent to Participate in Upcoming Investor Conferences

    WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Presentation webcast times will be posted on the website as they become available.Cowen 46th Annual Healthcare Conference at the Boston Marriott Copley in Boston, Massachusetts on March 3, 2026.Oppenheimer 36th Annual Healthcare MedTech and Services Conference to be

    2/26/26 5:00:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evolent Health downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Evolent Health from Overweight to Sector Weight

    2/25/26 7:39:36 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Domo downgraded by Citizens with a new price target

    Citizens downgraded Domo from Mkt Outperform to Mkt Underperform and set a new price target of $3.50

    2/13/26 8:28:18 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Evolent Health upgraded by Stephens with a new price target

    Stephens upgraded Evolent Health from Equal-Weight to Overweight and set a new price target of $7.00

    11/13/25 9:38:39 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $CMBM
    $DOMO
    $EVH
    $MDRX
    SEC Filings

    View All

    Domo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DOMO, INC. (0001505952) (Filer)

    3/10/26 4:17:37 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13D filed by Domo Inc.

    SCHEDULE 13D - DOMO, INC. (0001505952) (Subject)

    3/9/26 1:17:15 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Domo Inc.

    SCHEDULE 13G/A - DOMO, INC. (0001505952) (Subject)

    3/6/26 10:30:41 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Rpd Fund Management Llc claimed ownership of 4,613,726 units of Class B Common Stock (SEC Form 3)

    3 - DOMO, INC. (0001505952) (Issuer)

    3/9/26 1:20:40 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Blackley Seth covered exercise/tax liability with 51,326 shares and was granted 58,921 shares, increasing direct ownership by 0.92% to 836,962 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 6:02:31 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 4,910 shares and covered exercise/tax liability with 14,577 shares, decreasing direct ownership by 4% to 244,512 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/4/26 5:58:37 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Founder and CEO James Joshua G bought $165,897 worth of Class B Common Stock (13,025 units at $12.74), increasing direct ownership by 1% to 1,079,972 units (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    6/23/25 9:37:55 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Director Daniel Daniel David Iii bought $772,452 worth of Class B Common Stock (120,000 units at $6.44) (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    4/4/25 9:37:24 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Cambium Networks Announces Compliance with Minimum Bid Price Rule and Appointment of Interim Chief Financial Officer

    HOFFMAN ESTATES, Ill., Dec. 18, 2025 /PRNewswire/ -- Cambium Networks Corporation ("Cambium Networks", "Cambium" or the "Company") (NASDAQ:CMBM), a leading global provider of networking solutions, announced today that on December 12, 2025, the Company received a partial compliance letter ("Partial Compliance Letter") from the Nasdaq Hearings Panel (the "Hearings Panel") confirming that the Company is in compliance with the Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"), although it remains non-compliant with the Nasdaq Listing Rule 5250(c)(1) (the "Periodic Filing Rule"). The Hearings Panel also confirmed that it will maintain jurisdiction over the Company until April 8, 2026.

    12/18/25 6:15:00 AM ET
    $CMBM
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Financials

    Live finance-specific insights

    View All

    Domo Announces Fourth Quarter and Fiscal 2026 Financial Results

    Domo, Inc. (NASDAQ:DOMO) today announced results for its fiscal fourth quarter and year ended January 31, 2026. Fiscal Fourth Quarter Results Total revenue was $79.6 million, an increase of 1% year over year Subscription revenue was $73.4 million, an increase of 2% year over year Billings were $111.2 million, an increase of 8% year over year Subscription Remaining Performance Obligations (RPO) was $437.9 million as of January 31, 2026, an increase of 8% year over year Current subscription RPO was $227.0 million as of January 31, 2026, an increase of 1% year over year GAAP operating margin was negative 13%, an improvement of 2 percentage points year over year Non-GAAP

    3/10/26 4:05:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Domo Announces Timing of its Fourth Quarter and Full-Year Fiscal 2026 Earnings Conference Call

    Domo (NASDAQ:DOMO) today announced that results for its fourth quarter and full-year fiscal 2026 (ended January 31, 2026) will be released on Tuesday, March 10, 2026, after market close. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live dial-in is available at (877) 484-6065 or (201) 689-8846. A live webcast of the event will also be available on the Domo Investor Relations website at www.domo.com/IR. A replay will be available at (877) 660-6853 or (201) 612-7415 with access ID# 13758775 following the completion of the conference call until 11:59 p.m. (ET) on April 10, 2026. About Domo Do

    2/27/26 9:00:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025.Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model. We believe our total forecasted revenue growth of approximat

    2/24/26 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Domo Inc.

    SC 13G/A - DOMO, INC. (0001505952) (Subject)

    11/14/24 12:25:56 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology